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Abstract 
Trials of anti-inflammatory therapies in non-relapsing progressive multiple sclerosis (MS) have 
been stubbornly negative except recently for an anti-CD20 therapy in primary progressive MS and 
a S1P modulator siponimod in secondary progressive MS.  We argue that this might be because 
trials have been too short and have focused on assessing neuronal pathways, with insufficient 
reserve capacity, as the core component of the primary outcome. Delayed neuroaxonal 
degeneration primed by prior inflammation is not expected to respond to disease-modifying 
therapies targeting MS-specific mechanisms. However, anti-inflammatory therapies may modify 
these damaged pathways, but with a therapeutic lag that may take years to manifest. Based on 
these observations we propose that clinically apparent neurodegenerative components of 
progressive MS may occur in a length-dependent manner and asynchronously.  If this hypothesis is 
confirmed it may have major implications for the future design of progressive MS trials.  
Background 
Although multiple sclerosis (MS) typically begins with a relapsing course, over the lifetime of an 
individual, MS is dominated by the progressive phase of the disease. There is considerable overlap 
between the relapsing and progressive phases of the disease with a significant number of patients 
in the secondary progressive phase having relapses ​(Cohen et al., 2002)​. A minority of people 
present with a primary progressive course from the outset (PPMS). Despite presenting without 
relapses at onset a small proportion of people with PPMS go onto have superimposed relapses 
(Wolinsky and PROMiSe Trial Study Group, 2004)​. Against the backdrop of such substantial overlap 
between clinically described disease phases and/or MS phenotypes we propose to revisit the 
concept of MS-related disability as driven by three separate, but related, pathological phenomena, 
which are: 1) inflammation with accompanying demyelination, which can be acute and focal in 
new lesions/plaques,  or more chronic and diffuse and/or meningeal affecting lesions as well as 
”normal-appearing” areas of white and gray matter; 2) acute neuro-axonal damage, be it directly 
due to inflammation or as a result of other processes (see below) ​(Ferguson et al., 1997; Trapp et 
al., 1998; Wolinsky and PROMiSe Trial Study Group, 2004)​; and 3) delayed neuroaxonal loss, or 
neurodegeneration, of chronically demyelinated or vulnerable neuroaxonal tracts.  
Progressive disease as characterized by worsening disability, independent of relapses, is intricately 
driven by the focal and diffuse inflammation and delayed neuroaxonal loss (pathological processes 
1 & 3 above). Limited methodological approaches have been explored in clinical trials to 
disentangle these two related drivers of progression. At present there are very few options to 
modify progressive MS; the current approved  therapies only have an impact on clinically defined 
progression if there is evidence of ongoing relapses or focal MRI activity ​(Hawker et al., 2009) ​. A 
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significant unmet need persists for people with progressive MS, i.e. treatments targeting the 
delayed neurodegenerative component.  
When exactly the progressive phase of MS begins is subject to debate. Fred Lublin, an eminent 
neurologist from New York, is often quoted as saying ​‘I have difficulty defining secondary 
progressive MS, but I know it when I see it’​ ; a play on the supreme court judge ​Stewart​ Potter’s 
threshold test for what is pornography ​(Kalven, 1989)​. The definition of progressive MS disease 
has remained largely a clinical one based on the qualitative observation of “​steadily increasing 
objectively documented neurologic dysfunction/disability without unequivocal recovery​ ”. There is 
currently no consensus metric to identify and quantify progressive disease ​(Jacques and Lublin, 
2015)​.  
Evidence suggests the pathological substrates underlying progressive MS are chronic, widespread, 
inflammation, microglia activation ​(Frischer et al., 2009) ​, demyelination, gliosis, and particularly 
neuroaxonal loss ​(Lassmann et al., 2012)​. However, all these processes can be detected from 
disease onset when disease progression is not clinically apparent. MRI studies indicate progressive 
brain volume loss, or accelerated brain atrophy, from disease onset and occurs on average at 
similar rates in the early, and the late, stages of the disease ​(De Stefano et al., 2010) ​. More recent 
studies have shown that progressive brain atrophy can even be observed in people with 
radiologically-isolated syndromes (RIS), or pre-symptomatic MS ​(Amato et al., 2012; Rojas et al., 
2014)​. These observations underpin the impression that there is no sudden transition, or switch, 
between the relapsing and progressive phases of the disease. Rather, there is interplay over 
months and years of pathological processes leading to what we observe as the clinically apparent 
“chronic disease progression”. In reality the clinically detectable emergence of this transition 
occurs over a period of months to years and is commonly recognised retrospectively 
(Kremenchutzky et al., 2006)​.  
Evidence suggests that functional domains of the brain and spinal cord have reserve capacity 
(Mori et al., 2014)​. Functional domains can sometimes compensate for a substantial degree of 
neuro-axonal loss before progressive disease becomes clinically apparent ​(Schwartz et al., 2013) ​. 
Functional reserve, and partial or complete recovery from focal lesions, both contribute to 
complexity, and difficulty, in reliably detecting and monitoring disease progression early in the 
course of the disease.  
A widely accepted theory suggests axons that have survived an attack of focal inflammatory 
demyelination may become vulnerable and degenerate overtime. The proposed mechanisms 
underlying such delayed axonal degeneration include excitotoxicity, functional energy deficits and 
mitochondrial impairment, persistent demyelination, delayed axonal transport, age-related 
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neurodegeneration ​(Paz Soldán et al., 2015) ​, ongoing focal inflammation that may occur proximal 
or distal to previous MS lesions and diffuse innate inflammation ​(Campbell et al., 2014; Friese et 
al., 2014; Rao et al., 1981)​. Compensatory axonal sprouting to reinnervate vacated synapses, 
which is described in animal models ​(Liu and Chambers, 1958) ​, is hypothesised to increase the 
metabolic load of surviving axons thereby contributing to premature neuroaxonal death ​(Herndon, 
2002; Liu and Chambers, 1958)​. This is analogous to what happens to surviving lower motor 
neurons in the post-polio syndrome ​(Dalakas, 1995)​.  
Anatomical factors may also play a role. Certain anatomical sites in the brain and spinal cord are 
claimed to have predilection for developing MS lesions, for example the optic nerves, corpus 
callosum, paraventricular, deep and subcortical white matter, brain stem, cerebellum and cervical 
spinal cord ​(Hallpike et al., 1983)​. Involvement of these anatomical sites have largely been 
determined by gross pathological studies and supported by more recent MRI studies using 
conventional imaging sequences ​(Moore and Laule, 2012)​. However, contemporary pathological 
studies suggest that more than half of the lesion burden in MS occurs in the gray matter, both in 
the cortical and deep gray matter nuclei ​(Kutzelnigg and Lassmann, 2014; Rudick and Trapp, 2009)​. 
Based on these recent pathological observations it is difficult to link a characteristic anatomical 
pattern of white matter lesions to the overall distribution of focal and diffuse MS pathology, which 
challenges the dogma that has been used to classify MS as a white matter disease. The lack of 
anatomical specificity increases the likelihood of long fibre tracts having a greater disease burden 
than shorter tracts.  
Length-dependent axonopathy 
Clinical observations suggest that neuronal domains with longer central axonal projections are 
more likely to be involved early in the clinically apparent progressive phase of the disease (Figure 
1), for example the bladder and corticospinal, or pyramidal, projections to the lower limbs 
(Kremenchutzky et al., 2006)​. Involvement of these domains early in the course of the disease 
predicts a poorer outcome ​(Simone et al., 2002)​. If the distribution of MS lesions occurred 
randomly the functional subdomains, subserved by longer axons, are more likely to accumulate 
the greatest number of focal inflammatory lesions and hence be at the vanguard of the 
clinically-apparent progressive phase of the disease ​(Kremenchutzky et al., 2006)​. What protects 
neuronal domains from clinically progressive disease may be reserve capacity, i.e. the ability to 
compensate for neuroaxonal loss and the capacity for repair ​(Schwartz et al., 2013)​. A corollary is 
the shorter the neuronal pathway the less likely it is to have accumulated sufficient focal lesions 
and axonal loss to exhaust its reserve capacity (Figure 1 & 2). This might explain why the upper 
limb, brain stem motor function and the visual system appear to be rarely involved at the 
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beginning of the clinically-apparent progressive disease. The exception to the latter being 
progressive visual failure in women carriers of Leber’s hereditary optic neuropathy (LHON) who 
have a clinical phenotype that is indistinguishable from MS ​(Harding et al., 1992) ​. The latter 
condition though is arguably not MS, but a separate disease that mimics MS. The progressive 
visual failure that occurs in carriers of the mitochondrial DNA mutations which cause LHON hints 
at mitochondria, and cellular energetics imbalance, as playing a major role in delayed axonal loss. 
Differences in mitochondrial function between the spinal cord and brain may contribute to the 
selective vulnerability of spinal motor neurons in MS. The majority of upper motor neurons with 
long projection axons in the spinal cord contain mitochondria deficient in respiratory chain 
enzymes ​(Campbell et al., 2014)​. Spinal cord mitochondria retain considerably less calcium than 
brain mitochondria, possibly related to an increased set point concentration for calcium uptake 
(Morota et al., 2007)​; the different transport and retention capacity of calcium in spinal 
mitochondria is one mechanism that has been proposed to explain the increased susceptibility of 
the spinal cord to neurodegenerative processes. Additionally, the combined effects of injury 
occurring inside and outside the long projection axons at the edges of slowly expanding lesions in 
the spinal cord, enhance axonal energy failure and axonal degeneration in progressive MS 
(Campbell et al., 2014)​. 
Another anatomical factor that may make upper limb function more resistant to progression than 
the lower limbs is the smaller size of the motor units, with a proportionally larger area of the 
motor cortex, or homunculus, dedicated to hand, arm and shoulder function ​(Schieber, 2001)​.  
The length-dependent central axonopathy MS hypothesis (Figure 2) is not novel and has been 
proposed before ​(Garbern et al., 2002; Herndon, 2002) ​ and has been described in 
Pelizaeus-Merzbacher disease, a central demyelinating syndrome in which patients lack the major 
CNS myelin protein, proteolipid protein 1 ​(Garbern et al., 2002)​. What we are proposing, however, 
is that this length-dependent process might be explained by stochastic statistical phenomena that 
interact with anatomical, pathological and biological factors. In this model shorter axonal 
pathways may be involved earlier in the disease by chance and manifest clinically with progressive 
involvement; however, the initial onset of clinically progressive disease in the pathways subserved 
by shorter axons would be relatively uncommon early in the disease course (Figure 3).  
The sensory-motor paradox 
It is well known that sensory relapses are more frequent in early, or non-progressive, MS 
(Weinshenker et al., 1989)​. In comparison motor, sphincter and cerebellar “attacks”, or 
symptomatic exacerbations identified as such, are more common in older patients and in 
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progressive disease ​(Weinshenker et al., 1989)​. Similarly, sensory, visual and brainstem relapses 
are known to have a better recovery than motor relapses ​(Kalincik et al., 2014) ​. Why the paradox 
between the prognosis of sensory and motor attacks? We propose this paradox may be due to 
length-dependent mechanisms and the possibility that afferent/sensory systems may have a 
lower symptomatic threshold compared to efferent/motor systems when affected by MS lesions.  
The sensory system has shorter central axons ​(Webster, 1977)​ than the motor system 
(Wiesendanger, 1984)​, which may protect it if the length-dependent hypothesis is correct. Motor 
neurons are much longer than sensory neurons and hence more likely to acquire multiple hits 
that lead to more rapid or earlier exhaustion of functional reserve mechanisms and subsequent 
susceptibility to neurodegeneration. The architecture of the sensory system is such that afferent 
inputs go via first, second and third order neurons that communicate via synapses before 
reaching the cerebral cortex ​(Webster, 1977)​. Each relay axon is relatively short and hence this 
architecture may provide the sensory system relative protection from MS-associated 
neurodegeneration. The first-order sensory neurones are actually bipolar cells with their cell 
bodies residing outside the central nervous system in the posterior root ganglia (PRG) ​(Webster, 
1977)​. A demyelinating plaque affecting the central axonal process is therefore unlikely to kill the 
neuron residing outside the CNS in the PRG by the process of retrograde neurodegeneration. We 
know this because multiple sclerosis and sensory radiculopathies that destroy the central 
neuronal processes before they enter the spinal cord are characterised by preservation of sensory 
nerve action potentials (SNAPs), which indicates that the neuronal cell bodies and the peripheral 
axons are intact. The compartmentalisation of first order sensory neuronal cell bodies, outside the 
CNS, away from the MS pathology, may provide the sensory pathway with a better chance of 
recovery, via axonal sprouting or axonal regrowth. In comparison pyramidal, or motor, neurons 
extend their axons from the primary motor cortex to synapse on the anterior horn cells, or their 
equivalents, in the lateral columns of the spinal cord or brain stem, respectively. Importantly, 
there are no interneurons, which is why the motor neurones in the corticospinal tract are the 
longest neurones in the central nervous system. The cell bodies of pyramidal neurones also reside 
within the CNS, in layer five of the cerebral cortex, and hence are not protected from being 
directly involved by focal MS pathology.  
Why are sensory attacks more common early on in the course of the disease? 
 
In general sensory systems are designed for sensitivity; they need to detect changes in our 
environment so as to warn of us danger so that we can respond to them. From an evolutionary 
perspective our afferent/sensory systems are optimised for detection. A very large part of our 
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cortex is devoted to perceiving the senses. In fact most of the parietal, occipital and temporal 
lobes are devoted to perceiving, integrating and interpreting sensory inputs. In comparison, the 
efferent/motor system is optimised for action and much less of our cerebral cortex is dedicated to 
motor activity. As a result of its size (cortical area), and optimised sensitivity, a small lesion in the 
sensory pathways may be more likely to cause symptoms than a similar sized lesion in a motor 
pathway. This may explain why motor attacks have a worse outcome; larger lesions may be 
associated with greater damage.  
 
Pathological studies indicate that at least half the MS disease burden is found in cortical and 
subcortical gray matter. A small gray matter lesion in, or near, the sensory cortex could be a very 
common cause of early attacks. In comparison, a small lesion in the motor cortex may be less 
likely to cause symptoms. In comparison to the sensory system, the motor system is activated via 
reflexes, or through conscious volition. The motor system triggers a percept via sensory feedback 
loops; i.e. we only perceive weakness because the sensory receptors in the joints and muscles tell 
our brains that there is mismatch between what is meant to be happening and what is happening. 
The feedback loop results in the motor system having a much higher threshold for detecting 
change; hence small or relatively minor lesions in the motor system are likely to go unnoticed. 
This is backed-up by clinical observations; patients with MS are often unaware of detectable, but 
subtle, weakness in their limbs. This is not the case for the senses.  
 
Small lesions in motor pathways may only cause symptoms if the reserve of the pathway is 
reduced. Loss of reserve occurs over time and this may explain why motor attacks become more 
common with time. In comparison, loss of reserve in sensory pathways, and compensatory 
mechanisms, may reduce the sensitivity of perception and hence have the opposite effect, i.e. 
small lesions in compromised sensory pathways may be less likely to alter perception and cause 
symptoms. This could explain why sensory attacks become less frequent in advanced MS.  
 
Asynchronous progressive MS hypothesis 
The hypothesis that the neurodegenerative components of the progressive aspects of MS 
pathology might be a length-dependent, central, axonopathy would have implications for the 
design of clinical trials testing disease-modifying agents that may target progressive MS. One 
would assume that once a neuronal system has exhausted its reserve capacity and is gradually 
losing its function it may be very difficult to modify the processes causing delayed axonal fall-out, 
by targeting upstream MS-specific disease mechanisms, in particular autoimmune-driven focal 
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inflammation and demyelination ​(Coles et al., 2006) ​. In comparison, neuronal pathways that have 
significant neuronal reserve may be more amenable to disease modification, despite people 
having entered the clinically apparent progressive phase of MS in another system or domain. We 
refer to this as the asynchronous progressive MS hypothesis that suggests that neuronal domains 
might have different disease-course time windows in which disease-modifying therapies may have 
some benefit (Figure 3 and 4). This hypothesis may explain why so far anti-inflammatory therapies 
have been, in most phase 3 trials, unsuccessful in progressive MS using the Expanded Disability 
Status Scale (EDSS) as the primary outcome; particularly above EDSS 3.5, where the EDSS is 
predominantly an ambulation scale ​(Hobart et al., 2000)​. The corollary of the asynchronous 
progressive MS hypothesis is that trials in which the majority of subjects have a relatively high 
EDSS, measured over a relatively short time period of time, will only pick-up worsening in the 
longest neuronal systems at a stage where its reserve capacity is exhausted and less amenable to 
disease-modifying therapies. 
Expanded Disability Status Scale 
The EDSS has serious flaws in relation to its robustness as an outcome measure for trials in 
progressive MS ​(Hobart et al., 2000)​; it is non-linear, has ceiling and floor effects, has high intra- 
and inter-rater variability, represents a functional system-based impairment scale at low scores 
and a motor disability scale at high scores where it is dominated by ambulation or lower limb 
function ​(Hobart et al., 2000)​.  It also involves clinical decision making between the need for and 
acceptance of a walker versus a cane. The high end of the scale  may be its Achilles’ heel for 
progressive MS trials; particularly as it will be more difficult to reverse, or slow down, disability 
progression in a neuronal system that has already exhausted its reserve capacity using 
anti-inflammatory disease-modifying agents. Waiting for someone to enter the clinically-apparent 
progressive phase of MS, which is typically a progressive spastic paraparesis, sets the bar for 
success very high, particularly if the EDSS is used as the outcome measure. This has previously 
been referred to as the therapeutic window ​(Coles et al., 2006)​; i.e. if anti-inflammatory drugs are 
started late, too much damage has accrued to prevent the delayed consequences of previous focal 
inflammatory events running their course. This might imply that trials in the progressive phase of 
the disease using the EDSS as primary outcome may need to be longer and larger.  
Reserve Capacity 
Despite its limitations the EDSS may still provide robust enough observations to allow one to 
generate hypotheses. The length-dependent axonopathy hypothesis (Figure 2) provides an 
important conceptual framework to generate and test hypotheses. Once a neuronal system has 
lost it reserve capacity it is expected to be less capable of spontaneous recovery and hence less 
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prone to improve in function. This concept is supported by observations from the post-hoc 
analyses of relapse recovery from clinical attacks. In the pivotal natalizumab study ​(Polman et al., 
2006)​, subjects with an EDSS of less than 3.0 were more likely to make a full recovery from 
relapses than subjects with an EDSS equal to or greater than 3.0 ​(Lublin et al., 2014)​. Even the 
most potent anti-inflammatory drugs only appear to suppress new lesion formation and have 
limited effect on reducing pre-existing lesions ​(Soon et al., 2007; Sorensen et al., 2014)​. However, 
the latter may be time dependent; acute or active lesions may be amenable to treatments. For 
example, relapses under natalizumab treatment not only have a lower severity but also a higher 
probability of complete confirmed recovery ​(Lublin et al., 2014) ​. Similarly, fingolimod reduces the 
likelihood of gadolinium-enhancing lesions present on a baseline scan from converting into 
persistent black holes on T1-weighted scan ​(Radue E.W., Sprenger T., De Vera A., Francis G., 
Rochotte E., Tomic D., Kappos L., 2014)​; whether these observations are due to anti-inflammatory 
or neuroprotective effects of natalizumab and fingolimod is a moot point. It does, however, 
appear that as new focal lesions evolve there is a mix of pathogenic mechanisms whose 
contribution to damage varies over time; the molecular pathways that prevail in the early stage of 
a lesion appear to be more amenable to current therapies than those that are present at later 
stages.  However, both these drugs have failed in progressive disease despite their success in 
relapsing disease. 
Therapeutic lag 
Neuronal systems with sufficiently preserved functional reserve capacity, may demonstrate 
therapeutic lag (Figure 4) regarding the time it would take for an anti-inflammatory 
disease-modifying intervention to impact on the neurodegenerative components of its 
subsequent progressive disease course. Clinical progression in a neuronal pathway that has no 
reserve capacity may be primed by focal inflammatory events occurring months or years earlier as 
some of the pathological mechanisms underlying neuronal degeneration are likely to be delayed. 
Therefore, anti-inflammatory therapies that reduce new focal MS lesion accumulation may be 
unlikely to have an impact on neurodegenerative aspects of progression for several years (Figure 
4). The effects may also take some time to become detected through imaging modalities due to 
masking by the effects of pseudoatrophy (early rapid reduction in brain volume) ​(Koudriavtseva 
and Mainero, 2016)​. Therapeutic lag may manifest as a delay for a specific treatment in the 
slowing down, or a plateauing out, in the rate of progression in a particular pathway. 
Nevertheless, in subjects with reserve capacity an apparent impact on sustained disease 
progression may be seen much earlier provided that the anti-inflammatory intervention may 
either i) decrease more chronic and diffuse inflammation-mediated damage within white and gray 
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matter tissue, and/or ii) enhance capacity of the affected neuronal pathway to recover, partially or 
completely, via compensatory mechanisms such as local axonal plasticity, or synthesis of sodium 
channels across the demyelinated segment to restore conduction, remyelination, distal axonal 
sprouting and synaptogenesis and cortical or subcortical plasticity.  
The concept of a therapeutic lag in progressive MS is supported by the observation of randomised 
placebo-controlled study of interferon-beta-1b in primary progressive MS (Figure 3); at the end of 
the 2-year period of observation no clinical or MRI differences were seen between the placebo 
and active treatment arms  ​(Montalban et al., 2009)​. However, when the subjects were 
re-interrogated 5 years after the end of the trial, or 7 years after initial randomisation, clear 
differences in both clinical and MRI metrics were seen in favour of interferon-beta therapy ​(Tur et 
al., 2011)​. After 5 years without treatment the interferon beta-1b group had significantly better 
upper limb and cognitive outcomes, respectively, i.e. rather shorter neuronal systems which might 
have retained higher reserve capacity at time of drug intervention 5-7 years earlier. Consistently, 
the cohort who were treated with placebo for 2-years showed the greatest decrease in brain 
parenchymal fraction at year 7 ​(Tur et al., 2011) ​. Therefore, suppressing inflammation in 
progressive forms of MS may only manifest after 3-7 years; i.e. when the hypothesised 
progression primed by previous inflammatory events may have run its course. Therapeutic lag 
may thus take many years to emerge.  
Brain atrophy, an emerging biomarker that is reported to be an integrator of neuroaxonal loss in 
MS (​Bermel and Bakshi 2006)​ and correlates with T2 and T1 lesion volume (​Radue, Barkhof et al. 
2015)​, which are MRI markers of inflammation, demonstrates therapeutic lag ​(Koudriavtseva and 
Mainero, 2016)​.​ ​ When patients with active MS, as defined by the presence of 
gadolinium-enhancing lesions, are started on natalizumab brain atrophy rates only plateau-out or 
‘normalise’ in year 3 after starting treatment ​(Sastre-Garriga et al., 2014) ​. This would indicate that 
the processes responsible for causing neurons and axons to degenerate as a result of an 
inflammatory insult take many years to play out. Based on these and other observations one may 
question whether or not the duration of contemporary clinical trials currently underway in 
progressive forms of MS will be of a long enough duration to overcome the therapeutic lag. In 
their favour, however, is that some of these studies are event driven and are not of a fixed 
duration and, hence, will only close once enough clinical events have occurred.  
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Treatment effects in progressive MS evidenced by non-lower extremity neurological 
tests 
What do the length-dependent MS axonopathy hypothesis and the resulting asynchronous 
progressive MS (Figure 4) and therapeutic lag (Figure 3) hypotheses, mean for progressive MS? If 
therapeutic lag exists it would have implications for the optimal duration of doing progressive MS 
trials. It could mean if the hypothesis was to be confirmed that continuing to focus on longer 
tract-based neurological domains that may have exhausted their reserve capacity faster as the 
core components of primary outcome measures would imply that one would have to perform 
clinical trials that last 3-5 years and possibly longer. We may therefore consider shifting our focus 
to shorter tract-based pathways that may have higher reserve capacity and hence may be more 
likely to deliver a positive outcome in a shorter period of time.  
A closer look at the outcomes of some of the progressive MS trials supports our hypothesis. In the 
placebo-controlled, oral methotrexate, chronic progressive MS trial there was less progression of 
impairment as measured by upper-extremity function tests (9HPT and box-and-blocks test) in the 
treatment group compared to placebo, and no differences were noted in lower limb outcomes 
(EDSS and ambulation index) (​Goodkin, Rudick et al. 1995) ​. In the placebo-controlled 
intramuscular interferon (IFN) beta-1a, or IMPACT, SPMS study there was no benefit of IFNbeta-1a 
on the EDSS, which recruited subjects with an EDSS in range of 3.5-6.0 ​(Cohen et al., 2002)​. In 
comparison the median multiple sclerosis functional composite (MSFC) Z-score change was 
significantly reduced in the IFNbeta-1a treated subjects compared to placebo-treated subjects 
(Cohen et al., 2002)​. This was an effect driven by the 9HPT and the paced auditory serial addition 
(PASAT) tests, which assessed neuronal domains with shorter axonal pathways and potentially 
more preserved functional reserve in the target population. In the rituximab primary progressive 
trial (OLYMPUS study) the EDSS was shown to have a low sensitivity and reliability to detect 
disability progression ​(Hawker et al., 2009)​. When disability was analysed using different disability 
end points, the timed 25-foot walk test (T25FWT) and 9HPT were more sensitive to detect overall 
progression events, with the T25FWT being superior to the 9HPT in this respect ​(Zhang et al., 
2014)​. However, despite a lower observed event rate for 9HPT the rituximab treatment effect was 
slightly more pronounced on 9HPT progression (hazard ratio [95%CI]: 0.53 [0.31–0.93] for 
24-week confirmed progression) than on T25FW progression (hazard ratio [95%CI] 0.60 
[0.43–0.83] for 24-week confirmed progression). The observation in the OLYMPUS trial that 
T25FWT was overall more sensitive to change than 9HPT in both arms though rituximab treatment 
effect was merely higher on 9HPT, remains compatible with the length-dependent hypothesis. 
Nevertheless there might have been enough reserve capacity in the lower extremity motor system 
in this cohort of subjects to provide a positive T25FW read-out within 2 years. It is worth noting 
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that the majority of subjects enrolled in this study had an EDSS of less than 6.0 ​(Hawker et al., 
2009)​, which would favour the latter explanation.  
 
More recently in the SPMS natalizumab, or ASCEND, trial in which 63% of study subjects had an 
EDSS either 6.0 or 6.5, as predicted by the length-dependent axonopathy hypothesis, natalizumab 
had no effect on lower limb function (EDSS and T25FW), but ​a statistically significant treatment 
effect on reducing upper-limb disability progression unrelated to relapse  as measured using  the 
9HPT  ​(Steiner D., Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdova E, Jeffery D, 
Kapoor R, Miller A, Sellebjerg F, Yu B, Forrestal F, Liu K, Amarante D, Cadavid D, n.d.)​. In 
comparison, no differential treatment effect was seen between lower and upper limb function 
with fingolimod, compared to placebo, in the INFORMS PPMS trial ​(Lublin et al., 2016) ​. Despite 
fingolimod not having a significant treatment effect on lower limb and upper limb function it did 
have an impact on inflammation and significantly reduced relapses and focal MRI activity 
compared to placebo-treated patients ​(Lublin et al., 2016)​. Whether this disproves the 
length-dependent axonopathy hypothesis will require further post-hoc analyses of the data. 
 
In support of some of the aforementioned clinical observations are data from animal models of 
progressive MS. In chronic relapsing experimental allergic encephalomyelitis (CREAE) in the Biozzi 
ABH mouse, animals go through a relapsing-remitting phase before entering a secondary 
progressive phase (​Pryce, O'Neill et al. 2005,​ ​Al-Izki, Pryce et al. 2011,​ ​Al-Izki, Pryce et al. 2012) ​. In 
this model progressive disease initially manifests in the tail before affecting the hind limbs and 
finally the forelimbs (​Al-Izki, Pryce et al. 2012) ​; a pattern consistent with a central 
length-dependent axonopathy. Analysis of this model demonstrates that it recapitulates many of 
the clinical and pathological features seen in MS that have been linked to the progression, such as 
demyelination, neuroaxonal loss and gliosis and is refractory to peripheral immunosuppression 
similar to progressive MS ​(Al-Izki et al., 2012, 2011; Hampton et al., 2013; Pryce et al., 2005)​. This 
model provides experimental evidence that a multifocal inflammatory disease of the CNS 
manifests in a length-dependent manner and that progressive neurodegeneration occurs from 
disease onset but does not become clinically apparent until substantial loss of neuronal reserve is 
lost  ​(Al-Izki et al., 2012; Hampton et al., 2013; Pryce et al., 2005)​.  Interestingly, fingolimod did not 
impact on the progressive phase of this model, despite marked influences on relapsing attacks 
(Al-Izki et al., 2011)​, mirroring the observations in the PPMS  INFORMS study ​(Al-Izki et al., 2011; 
Lublin et al., 2016)​.  
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Non-MS related mechanisms contributing to progressive disease 
The length-dependent MS axonopathy model is not compatible with the recent results of the 
positive high-dose simvastatin trial in SPMS ​(Chataway et al., 2014) ​. This was a randomised 
double-blind trial that compared simvastatin, 80mg per day, to placebo over 2-years. The primary 
outcome measure was brain atrophy using volumetric MRI. Secondary outcomes included the 
EDSS measure. Whole brain atrophy rate in the placebo-treated group was 0.59% per year 
compared to 0.30% per year on simvastatin; the differences in reductions of -0.25% (95% CI -0.42 
to -0.09) was significant (p = 0.003). There was also a significant impact on worsening disability (p 
< 0.01); the mean EDSS increased from 5.9 to 6.4 in placebo-treated subjects and to a lesser 
extent, from 5.8 to 5.9, in the simvastatin-treated group, over 2 years. A length-dependent MS 
axonopathy model would not predict this outcome, as there was no therapeutic lag. An alternative 
explanation is that simvastatin may be working downstream of primary inflammatory 
demyelination and targeting pathological processes responsible for delayed neurodegeneration, 
or that the placebo arm may have had more activity prior to initiation of the study ​(Koudriavtseva 
and Mainero, 2016)​. If the simvastatin trial results are replicated it may indicate that the 
progressive phase of MS can be modified, possibly by targeting mechanisms that are not linked to, 
or are a consequence of, autoimmune-driven inflammatory demyelination.  
Conclusions 
In conclusion, if we want successful trials targeting the neurodegenerative pathological 
components of progressive MS disease we may have to rethink what outcome measures are most 
appropriate to use, with a particular focus on more sensitive and responsive outcome measures in 
neuronal domains that still retain substantial reserve capacity earlier in the disease course; for 
example, upper limb, cognitive and visual outcomes. Composite endpoints, 
including multiple disability measures might be superior to using the EDSS alone; through an 
increase in sensitivity and possibly specificity. ​C​omposite disability endpoints may overcome the 
over-emphasis of ambulation in EDSS and may therefore be more balanced towards functional 
domains that have sufficient reserve capacity. Should the length-dependent MS axonopathy 
hypothesis hold true, one may envisage an era of adaptive studies, for example in which futility 
analyses are done early using outcome measures that assess neuronal domains that may have 
higher reserve capacity after 2 years and if positive the study will be extended to look at outcome 
measures in pathways with more limited reserve capacity, i.e. lower limb motor function.  
As a potential driver of clinically asynchronous progression of MS, the length-dependent MS 
axonopathy hypothesis should be subject to appropriate and rigorous testing to yield 
evidence-based insights that may lead to customised study designs in the development of 
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effective treatments for progressive MS. Although the right trial designs, endpoints and futility 
analyses are critical, appropriate patient populations with more refined inclusion criteria, and/or 
pre-planned stratification of patients with different severity and duration of progressive disease 
may be required to improve trial design. The latter may dictate a different length of follow up for 
certain kind of patient populations to appropriately assess efficacy of putative DMTs. This would 
usher in an era of truly “patient-centric” and “disease-centric” trials. 
Dedication 
"If I have seen further, it is by standing upon the shoulders of giants"​  Sir Isaac Newton.  
Since the initial drafting of this paper it came to our attention that the concept of 
length-dependency underlying the clinical phenotype of multiple sclerosis over time has 
previously been observed and documented by John Kurtzke (figure 5) ​(Kurtzke, 2015)​. We 
therefore dedicate this paper to the memory of John Kurtzke a true giant in the field of multiple 
sclerosis who passed away on the 1 December 2015.  
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Figure 1 
 
Figure 1a-d: Proposed model underlying MS as a central length-dependent 
axonopathy 
Figures a-d demonstrates that if multiple sclerosis lesions occurred spatially randomly, pathways 
with longer axons would be affected more frequently by focal acute inflammatory lesions; in the 
example in figure 1a & b this is five times more likely. The greater lesion burden in the longer 
pathway will first result in anterograde, or Wallerian, degeneration (figure 1c) followed later by 
retrograde degeneration and subsequently neuronal loss (figure 1d).  
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Figure 2 
  
Figure 2a-e: Loss of functional reserve predisposes pathways to manifest earlier with 
clinically-apparent progressive MS 
Schematic example representation of the sequential paths to permanent functional deficit 
associated with delayed axonal loss following accumulation of focal inflammatory lesions. 
Compared to normal tissue (Figure 2a) the initial impact of multiple focal inflammatory lesions 
affecting the lower neuronal pathway (Figure 2b) may trigger a loss of 40% of its functioning 
neuroaxonal units x, which is able to recover function. Based on animal experiments this is 
hypothesised to be due to axonal plasticity, and axonal sprouting, from surviving neuroaxonal 
units (Figure 2c). However, the loss of reserve capacity in the lower pathway makes it more 
susceptible to damage from further focal inflammatory lesions (Figure 2d), with greater loss of 
function (Figure 2d and 2e) and the inability to recover completely (Figure 2f) leading to the 
emergence of clinically-apparent progressive disease.  
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Figure 3.  
 
Figure 3: Therapeutic lag 
Therapeutic lag refers to the observations that in patients with progressive disease it takes several 
years for anti-inflammatory therapies to have an impact on disease progression. Figure 3 
represents the randomised placebo-controlled study of interferon-beta-1b in primary progressive 
MS ​(Montalban et al., 2009)​. At the end of the two year trial there were no differences between 
the placebo and active treatment arms. However, at year 7, 5 years after the end of the trial, clear 
differences were seen in terms of both the clinical and MRI metrics in favour of the initial 
interferon-beta-1b therapy arm ​(Tur et al., 2011) ​. Therefore, suppressing inflammation in 
progressive forms of MS may only translate into a clinically meaningful outcome after lag period of 
3-7 years.  
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Figure 4. Redefining the therapeutic window in progressive MS 
 
Figure 4: The asynchronous progressive MS hypothesis 
This testable hypothesis predicts that neuronal domains may enter the clinically-apparent 
progressive phase of the disease at different rates depending on the length of the axons in the 
pathway and the reserve capacity of that pathway, i.e. its ability to compensate for ongoing or 
future damage. This hypothesis predicts that different neuronal domains will have different 
length-dependent therapeutic windows in which to respond to anti-inflammatory therapies that 
suppress ongoing inflammatory demyelinating lesions.  The neuronal domains that have not 
entered the clinically-apparent progressive phase of the disease, due to preservation of functional 
reserve, may only respond to anti-inflammatory therapies with a delay in the effect due to the 
delayed onset of clinical expression of neurodegenerative axonal loss; the so-called therapeutic 
lag. In contrast, the neuronal domains that have already entered the clinically-apparent 
progressive phase of the disease, due to loss of functional reserve, may  fail to respond to 
anti-inflammatory therapies.  
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Figure 5: ​Kurtzke’s schematic diagram of MS plaques in the brainstem and spinal cord with 
resulting clinical symptoms from earlier observations (UE – upper extremity, LE – lower extremity) 
(Kurtzke, 2015; Tur et al., 2011)​. Reproduced with permission of MSARD, Elsevier.  
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